MCM
RPRX icon

Marathon Capital Management’s Royalty Pharma RPRX Stock Holding History

Marathon Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$431K Buy
8,977
+1,379
+18% +$60.4K 0.1% 116
2025
Q4 		$294K Buy
7,598
+332
+5% +$12.7K 0.06% 133
2025
Q3 		$256K Buy
+7,266
New +$263K 0.06% 132

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Marathon Capital Management's RPRX Position: Q1 2026 in Review

Marathon Capital Management increased its Royalty Pharma (RPRX) stake by 18% in Q1 2026, buying an estimated $60.4K and bringing the position to 8,977 shares worth $431K. The position accounts for 0.1% of the portfolio, ranked #116.

Marathon Capital Management first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Marathon Capital Management held 8,977 shares of Royalty Pharma worth $431K as of Q1 2026.
  • Marathon Capital Management bought 1,379 Royalty Pharma shares in Q1 2026, an estimated $60.4K.
  • Royalty Pharma made up 0.1% of Marathon Capital Management's portfolio in Q1 2026, its #116 holding.
  • Marathon Capital Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.